This study surveyed six North American zoologic institutions to collect retrospective information on the incidence of ocular disease in the giant panda. Reported information included sex and age at presentation, as well as diagnosis, treatment, duration, and clinical outcome for each episode of ocular disease. Among the 42 animals included in the survey, 10 (23.8%) had clinical ocular abnormalities reported. Multiple disease episodes were reported in four animals, with 20 clinical episodes, and one additional animal who presented with corneal scarring from historic keratitis. Age at presentation varied from 0.4 to 26 yr (mean, 11.8 yr; median, 10.4 yr). Corneal abnormalities (including corneal opacity or haze, keratitis, corneal ulcers, and bullous keratopathy) were the most common pathologies reported, followed by conjunctivitis and/or ocular discharge. Additional reported abnormalities included limbal squamous cell carcinoma and lipid degeneration. Six cases resolved without intervention. Treatment protocols included topical and/or systemic medication with or without surgical intervention, which commonly resulted in resolution with or without persistent corneal scar. The prevalence of ocular disease identified in the giant panda in this study is higher than previous publications surveying ocular disease in the family Ursidae, indicating that this is an important source of morbidity in this species.
You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither BioOne nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the BioOne website.